Financial Data and Key Metrics Changes - The company closed the year with approximately $50 million in cash, having strengthened its cash position through various financing initiatives, including convertible note offerings and an ATM program [19][20] - The net loss from operations for 2025 was approximately $27 million, or $0.32 per share, compared to a net loss of $12.7 million, or $0.22 per share, in the previous year [22] - General and administrative expenses totaled approximately $12 million, an increase of about $2.4 million compared to the prior year, primarily due to higher stock-based compensation [22] Business Line Data and Key Metrics Changes - The Kellyton Graphite Plant is central to the company's vertically integrated strategy, with significant progress made in construction and operational readiness, including the installation of micronization and spheroidization equipment [12][14] - The Coosa Graphite Deposit is positioned as a long-term feedstock for the Kellyton plant, with permitting activities initiated and expected to take 12-24 months [16][18] Market Data and Key Metrics Changes - Global EV sales are projected to reach 27 million by 2030, up from 14 million in 2025, indicating strong long-term growth in the electric vehicle market [5] - Demand for natural graphite anode material is expected to grow by approximately 185% over the next decade, driven by the expansion of battery energy storage systems and EV adoption [5][6] Company Strategy and Development Direction - The company is focused on establishing a domestic supply chain for battery-grade graphite through its vertically integrated mine-to-market approach, which includes the Coosa Graphite Deposit and the Kellyton Graphite Plant [8][9] - The company aims to complete the financing needed for phase one of the Kellyton project, with a target to deliver battery-grade graphite within 12 months once financing is secured [10][11] Management's Comments on Operating Environment and Future Outlook - Management noted that while EV growth has moderated in the U.S., global adoption continues to rise, which is favorable for long-term demand for battery materials [4][5] - The current administration's support for critical minerals, including graphite, is increasing, with efforts to strengthen domestic supply chains recognized as essential for the North American battery industry [7][32] Other Important Information - The company received a U.S. patent for its graphite purification process, which avoids the use of hydrofluoric acid, supporting environmentally friendly production [13] - The company has approximately $72 million of remaining capacity under its ATM and $26 million under its ELOC, providing access to capital markets while maintaining a disciplined approach to dilution [21] Q&A Session Summary Question: How is the investor base viewing domestic supply for graphite amid geopolitical risks? - Management indicated that customers are increasingly seeking domestic supply contracts to insulate themselves from supply shocks and price volatility, positioning the company favorably due to its first-mover advantage [30][31] Question: How has governmental support manifested and changed in tone recently? - Management noted a shift in governmental support for critical minerals, with increased coordination among agencies and a letter of interest from the Ex-Im Bank, indicating a proactive approach to securing funding [32][33] Question: What is the status of the permitting process for the NPDES permit? - Management anticipates that the NPDES permit will be issued within the year, supported by the engagement of an experienced engineering firm [38]

Q4 FOURTH QUARTER 2025 UPDATE Strong quarter, pivotal year Musselwhite – Oct. 2025 FOR WA RD LO OK IN G STATE ME N TS AR E MA D E IN THI S P RE SE N TATIO N Cautionary disclaimers This presentation contains forward-looking statements and information within the meaning of Canadian securities law and United States securities laws, rules and legislation, including the provisions for "safe harbor" under the United States Private Securities Litigation Reform Act of 1995 (collectively, "forward-looking statements ...

These expectations are based on the present assumptions and analyses from the point of view of our management, in accordance with their experience and other factors such as the macroeconomic environment, market conditions in the electricity sector, and expected future results, many of which are not under our control. Important factors that could lead to significant differences between actual results and the projections about future events or results include: Cemig's business strategy, Brazilian and internat ...

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, increased to RMB 18.6 million from 0 in the previous year, primarily due to an upfront payment from an intellectual property license and technology transfer agreement with Joincare Group [21] - Other income decreased by RMB 72.6 million or 51.3% to RMB 68.8 million compared to RMB 141.4 million in 2024, mainly due to lower bank interest income and changes in government grants [21][22] - Research and development expenses declined by 14.8% to RMB 212.9 million from RMB 249.8 million in 2024, reflecting cost control measures [22][23] - Administrative expenses were RMB 199.5 million, a decrease of 28.5% compared to RMB 153.2 million in 2024, attributed to lower employee costs and adjustments in management compensation [23] Business Line Data and Key Metrics Changes - The company remains focused on advancing its HBV functional cure program, which is the top clinical priority, with key data reported and studies progressing towards registrational development [3][4] - The partnership with Joincare Group for soralimixin allows the company to prioritize resources on HBV programs while advancing the non-HBV portfolio [4][6] Market Data and Key Metrics Changes - The company is leveraging the strong research ecosystem in China to enhance its discovery capabilities, with new research infrastructure established in Beijing and Shanghai [9][36] - The company is exploring partnership opportunities for its HIV program and soralimixin rights in China, indicating a strategic approach to market expansion [32][36] Company Strategy and Development Direction - The company is sharpening its portfolio focus and expanding discovery capabilities, including integrating AI-enabled discovery tools into research workflows [4][8] - A disciplined partnering strategy is being employed to advance non-core assets while maintaining focus on areas with the strongest near-term opportunities [10][11] - The company aims to align management incentives with long-term shareholder value by significantly reducing senior management's annual bonuses [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the HBV program's potential, with important data expected to emerge in the coming months to inform future development stages [19][39] - The company is committed to maintaining a strong cash position, with bank deposits and cash equivalents amounting to RMB 1,941 million, expected to support operations beyond 2028 [22] Other Important Information - The company has built a robust internal discovery platform and is expected to nominate key new programs from its discovery efforts this year [4][9] - The company is open to both partnerships and self-development for its discovery programs, depending on expertise and market potential [37] Q&A Session Summary Question: Expectations for data from ENRICH and ENHANCE studies - Management expects data to emerge throughout the year, looking for immunologic priming effects and enhanced response rates in specific patient subgroups [26][27][28] Question: Focus areas for expanded discovery capabilities - The company is exploring candidates beyond infectious diseases, targeting chronic diseases with unmet medical needs, with specific areas to be disclosed later [30][31] Question: Updates on partnering strategy for non-core assets - The company continues to explore partnerships for its HIV program and soralimixin rights in China, with ongoing discussions with potential partners [32]

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, increased to CNY 18.6 million from 0 in the previous year, primarily due to an upfront payment from a licensing agreement with Joincare Group [21] - Other income decreased by CNY 72.6 million or 51.3% to CNY 68.8 million compared to CNY 141.4 million in 2024, mainly due to lower bank interest income and changes in government grants [21][22] - Research and development expenses declined by 14.8% to CNY 212.9 million from CNY 249.8 million in 2024, reflecting cost control measures [22][23] - Administrative expenses were CNY 199.5 million, a decrease of 28.5% compared to CNY 153.2 million in 2024, attributed to lower employee costs and adjustments in management compensation [23] Business Line Data and Key Metrics Changes - The company focused on advancing its HBV clinical programs, which remain the top clinical priority, with key data reported and studies advancing towards registrational pathways [3][4] - The partnership with Joincare Group for soralimixin allows the company to prioritize resources on HBV programs while advancing non-HBV assets [4][6] Market Data and Key Metrics Changes - The company is leveraging China's strong research ecosystem to enhance its discovery capabilities, with new research infrastructure established in Beijing and Shanghai [9][10] - The collaboration with OpenBench integrates AI-enabled drug discovery tools, enhancing the company's ability to analyze biological targets and design therapeutic molecules [10] Company Strategy and Development Direction - The company aims to maintain strong alignment with shareholder interests by reducing senior management's annual bonuses significantly, reinforcing the link between management incentives and long-term shareholder value [5] - The strategy includes a combination-based approach for HBV treatment, focusing on BRII-179 and elebsiran, with ongoing Phase 2b studies to evaluate their effectiveness [12][18] - The company is exploring partnership opportunities for its HIV program and other non-core assets, indicating a disciplined partnering strategy [6][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong cash position, expecting current cash to support operations beyond 2028 while continuing to invest in core programs [22][23] - The company anticipates important milestones for its HBV program in the coming year, with data expected to inform the next stage of development [19][39] Other Important Information - The company has built a robust internal discovery platform and is expanding its capabilities to support future pipeline development [9][24] - The focus on chronic diseases and unmet medical needs indicates a strategic shift beyond infectious diseases [31][36] Q&A Session Summary Question: Expectations for data from ENRICH and ENHANCE studies - Management expects data to emerge throughout the year, looking for immunologic priming effects and enhanced response rates in specific patient subgroups [26][27] Question: Focus areas for expanded discovery capabilities - The company is exploring candidates in chronic diseases and common diseases with unmet medical needs, with specific areas to be disclosed later [30][31] Question: Updates on partnering strategy for non-core assets - The company continues to explore partnerships for its HIV program and other assets, with ongoing discussions with potential partners [32][36]

Financial Data and Key Metrics Changes - Milestone Pharmaceuticals reported $1.5 million in revenue for Q4 2025, with no revenue comparables in 2024, reflecting earnings under a licensing collaboration agreement following FDA approval of CARDAMYST [21] - R&D expenses for Q4 2025 were $5.5 million, up from $3.9 million in Q4 2024, with full-year R&D expenses at $18.1 million compared to $14.4 million in 2024 [21][22] - G&A expenses increased to $5.1 million in Q4 2025 from $4.0 million in the prior quarter, with full-year G&A expenses at $17.3 million compared to $16.7 million in 2024 [22][23] - Commercial expenses surged to $8.2 million in Q4 2025 from $4.4 million in Q4 2024, with full-year commercial expenses at $28.3 million compared to $11 million in 2024 [23] - The net loss for Q4 2025 was $17.4 million or $0.16 per share, compared to a net loss of $12.4 million or $0.19 per share in Q4 2024, with a full-year net loss of $63.1 million or $0.75 per share compared to $41.5 million or $0.67 per share in 2024 [24] Business Line Data and Key Metrics Changes - The launch of CARDAMYST, an etripamil nasal spray for PSVT, marks a significant new therapeutic option for over 2 million patients, with the commercial strategy focused on driving new patient starts and achieving commercial coverage [5][7] - The commercial team has engaged with approximately 10,000 providers who manage half of the 1 million patients expected to receive treatment for PSVT in 2026 [12] Market Data and Key Metrics Changes - The PSVT market is identified as a clearly defined opportunity within cardiovascular specialty pharma, with efforts to demonstrate the value proposition of CARDAMYST to payers [13] - Initial feedback from prescribers has been positive, with over 150 prescriptions filled in the first month of launch, primarily from new patient starts [16] Company Strategy and Development Direction - The FDA approval of CARDAMYST is seen as a foundation for value creation, with plans to leverage clinical data for marketing approvals in other regions, including Europe [8][9] - The company aims to establish a strong commercial franchise and reduce reliance on emergency department care through the self-administered CARDAMYST [26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early launch phase, noting that while it is too early to identify durable patterns, they expect prescription volume to increase and commercial coverage to expand over time [20] - The company is focused on ensuring that physicians can prescribe CARDAMYST, patients can access it, and payers recognize the demand in the marketplace [20] Other Important Information - The company reported a pro forma cash figure of approximately $200 million, supporting the successful launch of CARDAMYST and providing an operating runway into late 2027 [10][24] - The leadership team has been enhanced with the addition of David Sandoval as General Counsel and Chief Compliance Officer [10] Q&A Session Summary Question: Feedback on CARDAMYST launch and coverage denial reasons - Management noted broad adoption among cardiologists and advanced practice providers, with coverage denials primarily due to paperwork requirements for patient eligibility [28][31] Question: Reimbursement timelines and patient access - Management indicated that scripts are being filled within days to weeks after engaging the system, with ongoing efforts to support patients during the reimbursement process [35][38] Question: Replacement therapies for CARDAMYST and patient feedback - Management reported a broad range of patients using CARDAMYST, including those awaiting ablation, with positive early feedback from social media indicating excitement about having the treatment available [46][49] Question: Contracting strategy and formulary positioning - Management aims for open access with reasonable coverage terms, expecting a 50/50 split between commercial and Medicare patients, and is actively engaging payers for coverage [58][61]

Financial Data and Key Metrics Changes - Milestone Pharmaceuticals reported $1.5 million in revenue for Q4 2025, with no revenue comparables in 2024, reflecting earnings under a licensing collaboration agreement following FDA approval of CARDAMYST [21] - R&D expenses for Q4 2025 were $5.5 million, up from $3.9 million in Q4 2024, with full-year R&D expenses at $18.1 million compared to $14.4 million in 2024 [21][22] - G&A expenses increased to $5.1 million in Q4 2025 from $4.0 million in the prior quarter, with full-year G&A expenses at $17.3 million compared to $16.7 million in 2024 [22][23] - Commercial expenses surged to $8.2 million in Q4 2025 from $4.4 million in Q4 2024, with full-year commercial expenses at $28.3 million compared to $11 million in 2024 [23] - The net loss for Q4 2025 was $17.4 million or $0.16 per share, compared to a net loss of $12.4 million or $0.19 per share in Q4 2024 [24] - As of December 31, 2025, the company had $106 million in cash equivalents and short-term investments, with a pro forma cash figure of approximately $200 million after subsequent financing activities [24][25] Business Line Data and Key Metrics Changes - The launch of CARDAMYST, an etripamil nasal spray for PSVT, marks a significant new therapeutic option for over 2 million patients, with the commercial strategy focused on driving new patient starts and achieving commercial coverage [5][7] - The commercial team has begun executing the launch strategy, with CARDAMYST available in retail pharmacies within six weeks of FDA approval [12][13] Market Data and Key Metrics Changes - The company is targeting around 10,000 healthcare providers who manage half of the 1 million patients with PSVT expected to receive treatment in 2026 [12] - Initial feedback from prescribers has been positive, with over 150 prescriptions filled in the first month, primarily from new patient starts [16][20] Company Strategy and Development Direction - The FDA approval of CARDAMYST is seen as a foundation for value creation, with plans to leverage clinical data for marketing approvals in other regions, including Europe [9] - The company aims to establish a strong commercial franchise in acute cardiovascular therapy, focusing on making CARDAMYST accessible and affordable for patients [20][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early launch phase, noting that while it is too early to identify durable patterns, they expect prescription volume to increase and commercial coverage to expand over time [20][26] - The company is actively engaging with payers to demonstrate the value of CARDAMYST, aiming for broad coverage while managing the natural dampening effect of reimbursement processes [53][54] Other Important Information - The company has enhanced its leadership team with the addition of David Sandoval as General Counsel and Chief Compliance Officer, expected to support long-term growth [10] Q&A Session Summary Question: Feedback on CARDAMYST launch and coverage denial reasons - Management noted broad adoption across cardiology and electrophysiology, with APPs being key prescribers; coverage denials are primarily due to paperwork requirements for patient eligibility [28][31] Question: Reimbursement timelines and patient access - Management indicated that scripts are being filled within days to weeks once the system is engaged, with ongoing efforts to support patients during the reimbursement process [35][38] Question: Current prescribing trends and patient demographics - Management reported a diverse patient mix, with some using CARDAMYST before ablation or as a routine course; they are optimistic about the drug's broad applicability [46][48] Question: Contracting strategy and formulary positioning - The company aims for open access with reasonable prior authorization requirements, expecting a 50/50 split between commercial and Medicare coverage [58][61]

Helios Technologies 2026 Investor Day Summary Company Overview - **Company**: Helios Technologies (NYSE: HLIO) - **Event**: 2026 Investor Day held on March 20, 2026 - **Recent Financial Performance**: Reported 2025 results of $839 million, with a pro forma view of $792 million after a divestiture [7][8] Core Industry Insights - **Segments**: Helios operates in two main segments: Hydraulics and Electronics - **Revenue Distribution**: Electronics accounts for nearly 40% of total revenues; OEMs represent about 57% of sales channels [8][20] - **Market Dynamics**: The company has diversified end markets, reducing reliance on any single customer or market [22] Strategic Initiatives - **CORE 2030 Strategy**: Aims to double sales to $1.6 billion by 2030, with a commitment to 5% organic growth annually [48][52] - **Financial Goals**: Targeting adjusted EBITDA margins exceeding 25% and operating income margins of 20% [52] - **Product Development**: Launched 11 new products in 2025, contributing to incremental revenue streams [39] Leadership and Governance - **Leadership Changes**: Sean Bagan appointed as President and CEO in January 2025, emphasizing a disciplined approach to financial forecasting and strategic planning [10][13] - **Board Refreshment**: Over 70% of the board has been refreshed in the last five years, with Laura Dempsey Brown as the new chair [4][30] Financial Health - **Debt Management**: Significant progress in reducing debt, with $153 million paid down over two years, resulting in a leverage ratio below 2x [45] - **Shareholder Returns**: Initiated a share repurchase program, returning capital to shareholders at an average share price of $55 [46] Market Opportunities - **Electronics Segment Growth**: Focus on expanding in underserved markets, particularly in EMEA and APAC regions [60] - **Health and Wellness Market**: Balboa Water Group leads in health and wellness, with ongoing growth opportunities [64] Employee Engagement - **Employee Statistics**: Average tenure of 9 years, with a notable increase in employee net promoter score by 13 points [41] - **Talent Development**: Initiatives like the Helios Leadership Academy aim to cultivate the next generation of leaders [43] Challenges and Resilience - **Pandemic Impact**: Experienced organic sales declines and margin compression post-pandemic, but returned to growth after 12 quarters of decline [9][13] - **Crisis Management**: Successfully navigated local challenges, including hurricanes, which fostered organizational unity and resilience [11][12] Conclusion - **Future Outlook**: Helios Technologies is positioned for growth with a clear strategy, strong leadership, and a commitment to innovation and customer satisfaction [14][47]

Financial Data and Key Metrics Changes - Milestone Pharmaceuticals reported $1.5 million in revenue for Q4 2025, with no revenue comparables in 2024, reflecting earnings under a licensing collaboration agreement following FDA approval of CARDAMYST [19] - R&D expenses for Q4 2025 were $5.5 million, up from $3.9 million in Q4 2024, with full-year R&D expenses at $18.1 million compared to $14.4 million in 2024 [19] - G&A expenses increased to $5.1 million in Q4 2025 from $4.0 million in the prior quarter, with full-year G&A expenses at $17.3 million compared to $16.7 million in 2024 [20] - Commercial expenses rose significantly to $8.2 million in Q4 2025 from $4.4 million in Q4 2024, with full-year commercial expenses at $28.3 million compared to $11 million in 2024 [20] - The net loss for Q4 2025 was $17.4 million or $0.16 per share, compared to a net loss of $12.4 million or $0.19 per share in Q4 2024 [20] - Full-year net loss was $63.1 million or $0.75 per share, compared to $41.5 million or $0.67 per share in 2024 [21] Business Line Data and Key Metrics Changes - The launch of CARDAMYST is seen as a pivotal moment for the company, targeting over 2 million patients with PSVT, marking the first new therapeutic option in 30 years [4][5] - The commercial strategy focuses on driving new patient starts and achieving commercial coverage, with a sales force of approximately 60 representatives targeting around 10,000 providers [10] Market Data and Key Metrics Changes - The company has filed a marketing authorization application for CARDAMYST in Europe, with expectations for a decision in the first half of 2027 [7] - The company is actively engaging with payers to demonstrate the value proposition of CARDAMYST, aiming to reduce emergency department visits and hospital utilization [11] Company Strategy and Development Direction - The FDA approval of CARDAMYST is viewed as a foundation for value creation, with a focus on building a strong commercial franchise [5] - The company aims to leverage comprehensive clinical data to seek marketing approvals in other regions, enhancing the credibility of CARDAMYST [6] - The strategy includes ensuring a positive initial experience for patients and prescribers, with a focus on accessibility and affordability [12][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early feedback from prescribers and the initial launch of CARDAMYST, indicating strong demand generation [12][18] - The company anticipates prescription volume to increase and commercial coverage to expand over time, with more meaningful progress expected in the latter half of the year [18] Other Important Information - The company reported a pro forma estimated cash figure of $200 million, supporting the successful launch of CARDAMYST and providing an operating runway into late 2027 [7][22] - The leadership team has been enhanced with the addition of David Sandoval as General Counsel and Chief Compliance Officer [8] Q&A Session Summary Question: Feedback on CARDAMYST launch and coverage denial reasons - Management noted a broad mix of prescribers adopting CARDAMYST, including cardiologists and advanced practice providers, with coverage denials primarily due to paperwork requirements for patient eligibility [26][28] Question: Reimbursement timelines and patient access - Management indicated that scripts are being filled within days to weeks once the system is engaged, with ongoing efforts to support patients in accessing the drug during the delay period [32][35] Question: Current prescribing trends and patient mix - Management reported that CARDAMYST is being prescribed to a diverse patient group, including those awaiting ablation and those with existing medications, but emphasized that it is too early to identify specific trends [43][44] Question: Contracting strategy and formulary positioning - The company aims for broad access with reasonable coverage terms, targeting commercial plans first, with Medicare coverage expected to follow in 2027 [50][57]

Financial Data and Key Metrics Changes - In 2025, the company's revenue increased to CNY 18.6 million from 0 in the previous year, primarily due to an upfront payment from a licensing agreement with Joincare Group [20] - Other income decreased by CNY 72.6 million or 51.3% to CNY 68.8 million compared to CNY 141.4 million in 2024, mainly due to lower bank interest income and changes in government grant income [21] - Research and development expenses declined by 14.8% to CNY 212.9 million from CNY 249.8 million in 2024, reflecting cost control measures [22] - Administrative expenses were CNY 199.5 million, a decline of 28.5% compared to CNY 153.2 million in 2024, attributed to lower employee costs and organizational optimization [23] - As of December 31, 2025, cash and cash equivalents were CNY 1,941 million, expected to support operations beyond 2028 [22] Business Line Data and Key Metrics Changes - The company focused on advancing its HBV functional cure program, which remains its top clinical priority, with key data reported and studies progressing towards registrational pathways [3][4] - The partnership with Joincare Group for soralimixin allows the company to prioritize resources on HBV programs while advancing non-HBV assets [4][5] Market Data and Key Metrics Changes - The company is leveraging China's strong research ecosystem to enhance its discovery capabilities, establishing labs in Beijing and Shanghai to support early-stage drug discovery [9][36] - The company is exploring partnership opportunities for its HIV program and other non-core assets, indicating a strategic approach to market engagement [32][38] Company Strategy and Development Direction - The company aims to maintain strong alignment with shareholder interests by reducing senior management's annual bonuses to approximately one quarter of their original level [5] - The strategy includes a disciplined partnering approach for non-HBV assets while focusing on areas with the strongest near-term opportunities [10][11] - The company plans to introduce new programs from its discovery platform and define its development strategy around them [24][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the HBV program's potential, expecting important data to emerge later this year to inform the next stage of development [40] - The company is aware of the competitive landscape and aims to differentiate its offerings while exploring the potential of its expanded discovery capabilities [29][36] Other Important Information - The company has made significant investments in building its internal research capabilities and integrating AI-enabled discovery tools into its workflow [8][9] - The company is open to both internal development and partnerships for its discovery programs, depending on expertise and market potential [38] Q&A Session Summary Question: Expectations for data from ENRICH and ENHANCE studies - Management expects data to emerge throughout the year, looking for immunologic priming effects and enhanced response rates in the ENRICH study, and a 10% or better response in the ENHANCE study compared to previous results [26][27][28] Question: Focus areas for expanded discovery capabilities - The company is expanding beyond infectious diseases to include chronic diseases with unmet medical needs, with specific areas to be disclosed later [30][31] Question: Updates on partnering strategy for non-core assets - The company continues to explore partnerships for its HIV program and other assets, with ongoing discussions with potential partners [32]